ROLE OF HORMONAL ASSAY IN DIAGNOSING PCOD DR GAANA SREENIVAS (JSS,MYSURU)

Similar documents
Polycystic Ovary Syndrome HEATHER BURKS, MD OU PHYSICIANS REPRODUCTIVE MEDICINE SEPTEMBER 21, 2018

Polycystic Ovarian Syndrome (PCOS) LOGO

Case Questions. Polycystic Ovarian Syndrome: Treatment Goals and Options. Differential Diagnosis of Hyperandrogenic Anovulation

Polycystic Ovary Syndrome

Overview of Reproductive Endocrinology

Hormone Balance - Female Report SAMPLE. result graph based on Luteal Phase. result graph based on Luteal Phase

Case. 24 year old female presented to your office complaining of excess hair growth on her face and abdomen. Questions?

Test Briefing on Hormonal Disorders and Infertility

16 YEAR-OLD OBESE FEMALE WITH OLIGOMENORRHEA

Polycystic Ovary Syndrome

POLYCYSTIC OVARIAN SYNDROME Laura Tatpati, MD Reproductive Endocrinology and Infertility. Based on: ACOG No. 108 Oct 2009; reaffirmed 2015

Nitasha Garg 1 Harkiran Kaur Khaira. About the Author

INSULIN RESISTANCE, POLYCYSTIC OVARIAN SYNDROME An Overview

Investigation of adrenal functions in patients with idiopathic hyperandrogenemia

Polycystic Ovarian Syndrome. Heidi Hallonquist, MD Concord Hospital Concord Obstetrics and Gynecology

Polycystic Ovarian Syndrome: Diagnosis, Preconceptional Management and Health Risks. Kate D. Schoyer, M.D. May 6, 2016

Polycystic Ovarian Syndrome: Diagnosis, Preconceptional Management and Health Risks

PCOS and Obesity DUB is better treated by OCPs

Title of Guideline (must include the word Guideline (not protocol, policy, procedure etc)

Dr Stella Milsom. Endocrinologist Fertility Associates Auckland. 12:30-12:40 When Puberty is PCO

GONADAL FUNCTION: An Overview

SAMPLE REPORT. Order Number: PATIENT. Age: 40 Sex: F MRN:

12/27/2013. Kristen Cain, MD FACOG Reproductive Medicine Institute Sanford Health, Fargo ND

Hyperandrogenism. Dr Jack Biko. MB. BCh (Wits), MMED O & G (Pret), FCOG (SA), Dip Advanced Endoscopic Surgery(Kiel, Germany)

Endocrine control of female reproductive function

Prof.Dr. Nabil Lymon Head of Internal Medicine Department

Lab Guide Endocrine Section Lab Guide

12/13/2017. Important references for PCOS. Polycystic Ovarian Syndrome (PCOS) for the Family Physician. 35 year old obese woman

Polycystic Ovary Syndrome (PCOS):

Polycystic Ovary Disease: A Common Endocrine Disorder in Women


Abstract. Introduction. RBMOnline - Vol 10. No Reproductive BioMedicine Online; on web 15 November 2004

Clinical and endocrine characteristics of the main polycystic ovary syndrome phenotypes

Can Sex hormone Binding Globulin Considered as a Predictor of Response to Pharmacological Treatment in Women with Polycystic Ovary Syndrome?

Reproductive FSH. Analyte Information

Metfornim and Pioglitazone in polycystic ovarian syndrome: A comparative study

S. AMH in PCOS Research Insights beyond a Diagnostic Marker

Polycystic Ovary Syndrome

JMSCR Vol 05 Issue 05 Page May 2017

SCHOOL OF MEDICINE AND HEALTH SCIENCES DIVISION OF BASIC MEDICAL SCIENCES DISCIPLINE OF BIOCHEMISTRY & MOLECULAR BIOLOGY

Reproductive outcome in women with body weight disturbances

METABOLIC RISK MARKERS IN WOMEN WITH POLYCYSTIC OVARIAN MORPHOLOGY

New PCOS guidelines: What s relevant to general practice

Abnormal Uterine Bleeding Case Studies

Achieving Pregnancy: Obesity and Infertility. Jordan Vaughan, MSN, APN, WHNP-BC Women s Health Nurse Practitioner Nashville Fertility Center

Metformin and Pioglitazone in Polycystic Ovarian Syndrome: A Comparative Study

CASE 41. What is the pathophysiologic cause of her amenorrhea? Which cells in the ovary secrete estrogen?

Polycystic ovary syndrome

Hd Hydroxylase. Cholesterol. 17-OH Pregnenolne DHEA Andrstendiol. Pregnenolone. 17-OH Progestrone. Androstendione. Progestrone.

Original Investigation. 94 Endocrine Oncology and Metabolism. Jovanovska et al

By Jennifer F. Teskey, MD; Heather J. Dean, MD, FRCPC; and Elizabeth AC Sellers, MSc, MD, FRCPC. amenorrhea. Following menarche 3. How to treat PCOS.

Amenorrhoea: polycystic ovary syndrome

Reproductive Health and Pituitary Disease

Co-Administration of Metformin and N-Acetyl Cysteine Fails to Improve Clinical Manifestations in PCOS Individual Undergoing ICSI

Polycystic ovarian disease and Endometriosis

2-Hypertrichosis:- Hypertrichosis is the

Female Reproductive Endocrinology

INFERTILITY CAUSES. Basic evaluation of the female

THE PREVALENCE AND ETIOLOGY OF POLYCYSTIC OVARIAN SYNDROME (PCOS) AS A CAUSE OF FEMALE INFERTILITY IN CENTRAL TRAVANCORE

Antim ullerian hormone and polycystic ovary syndrome

LABORATORY TESTS IN DIAGNOSIS OF FEMALE INFERTILITY

Reproductive Testing: Less is More G. Wright Bates, Jr., M.D. Professor and Director Reproductive Endocrinology and Infertility Objectives

Hormone. Free Androgen Index. 2-Hydroxyestrone. Reference Range. Hormone. Estrone Ratio. Free Androgen Index

clinical outcome and hormone profiles before and after laparoscopic electroincision of the ovaries in women with polycystic ovary syndrome

Is anti-mullerian hormone an indicator of potential polycystic ovary syndrome in prepubertal girls with simple obesity?

lactotrophs 120 min- FSH 60 min- LH Hypothalamus GnRH pituitary Estradiol +/- Progesterone _ FSH L H Ovary Uterus Ovulation Antral follicle >2mm

Assisted Reproductive. Technologies: Present and. Future

Bilan Hormonal. Question posée. Ovulation? Qualité de l ovulation? Vieillissement ovarien? Fonction thyroïdienne Fonction surrénalienne

Study No.: Title: Rationale: Phase Study Period: Study Design: Centres: Indication: Treatment: Objectives: Primary Outcome/Efficacy Variable:

Prevalence of polycystic ovarian syndrome in the Buraimi region of Oman

Can high serum anti-müllerian hormone levels predict the phenotypes of polycystic ovary syndrome (PCOS) and metabolic disturbances in PCOS patients?

WEIGHT GAIN DURING MENOPAUSE EMERGING RESEARCH

Senior resident 5 lll rd year P.G. student

Estimation of serum 25 hydroxy vitamin D level and its correlation with metabolic and endocrine dysregulation in women with PCOS

Clinical evaluation of hirsutism in South India

University of Cape Town

Approach to ovulation induction and superovulation in women with a history of infertility. Anatte E. Karmon, MD

POLYCYSTıC OVARY SYNDROME (PCOS) New Perspectives. Michel Abou Abdallah, MD. Reproductive Endocrinology

PREVALENCE OF METABOLIC SYNDROME IN WOMEN WITH POLYCYSTIC OVARIAN SYNDROME A CROSS SECTIONAL STUDY THE TAMILNADU. Dr.M.G.R.

POLYCYSTIC OVARIAN SYNDROME WHERE WE ARE AT IN 2018

Investigation: The Human Menstrual Cycle Research Question: How do hormones control the menstrual cycle?

Infertility. Review and Update Clifford C. Hayslip MD Intrauterine Inseminations

13 th Annual Women s Health Day PCOS. Saturday 02/09/2017 Dr Mathias Epee-Bekima O&G Consultant KEMH

POTION OR POISON? MEDICAL TREATMENT ALTERNATIVES TO THE PILL. Lester Ruppersberger, D.O., FACOOG,CNFPI NFP only Gynecologist

Disclosure. Outline. Obesity: Endocrine Issues as the Cause and as the Effect 4/5/2016

Ontogeny of the new hypo-androgenic PCOS phenotype

PCOS Awareness Symposium Atlanta September 24 th, Preventing Diabetes & Cardiovascular Disease in PCOS

14 Girl with Cushing s Disease: An Update. Kristen Dillard, MD Endorama October 17, 2013

Gonadotrophin treatment in patients with Polycystic Ovary Syndrome

DOES INSULIN RESISTANCE CAUSE HYPERANDROGENEMIA OR HYPERANDROGENEMIA CAUSES INSULIN RESISTANCE IN PCOS

Polycystic Ovary Syndrome Therapy Dr. Pilar Vigil MD, PhD, FACOG

Diabetes and Cardiovascular Risks in the Polycystic Ovary Syndrome

Stelios Mantis, MD DuPage Medical Group Pediatric Endocrinology

1. During the follicular phase of the ovarian cycle, the hypothalamus releases GnRH.

PCOS guidelines: What s relevant to general practice

POLYCYSTIC OVARY SYNDROME INA S. IRABON,MD, FPOGS,FPSRM,FPSGE OBSTETRICS AND GYNECOLOGY REPRODUCTIVE ENDOCRINOLOGY AND INFERTILITY

JMSCR Vol 05 Issue 04 Page April 2017

REI CASE(S) Laura L. Tatpati, MD Division of REI, Dept of OB/GYN KUSM - W

The Impact of Insulin Resistance on Long-Term Health in PCOS

OVERVIEW. FEMM (Fertility Education & Medical Management) is headquartered in New York City, NY. 1

Transcription:

ROLE OF HORMONAL ASSAY IN DIAGNOSING PCOD DR GAANA SREENIVAS (JSS,MYSURU)

In 1935, Stein and Leventhal described 7 women with bilateral enlarged PCO, amenorrhea or irregular menses, infertility and masculinizing features. This paper introduced clinicians to the concept of reproductive endocrinopathies

PCOS is a complex endocrine disorder affecting women of child bearing age characterised by increased androgen production and ovulatory dysfunction. It is the most common endocrine disorder of reproductiveaged women and affects approximately 5 to 10 %.(Norman et all 2007)

PCOS is the leading cause of anovulatory infertility and hirsutism 20-33% of all reproductive age group have polycystic ovaries 5-10% of all reproductive age group have PCOS 87% of women have oligomenorrhoea 26% of them have amenorrhoea 50% of them present with infertility 50% of women with recurrent miscarriages

Laboratory Investigations No consensus regarding specific lab test for PCOS To document hyperandrogenism. To rule out other endocrinopathies. Look for metabolic abnormalities (commonly seen with PCOS). The underlying defects in PCOS are still unclear, however insulin resistance and metabolic syndrome are common in both obese and non-obese PCOS patients, so that evaluation of glucose tolerance is recommended.

Following hormone levels are measured when considering a PCOS diagnosis LH FSH TOTAL AND FREE TESTOSTERONE DEHYDROEPIANDROSTERONE SULFATE (DHEA S) PROLACTIN ANDROSTEINDIONE PROGESTERONE ESTROGEN OTHERS: TSH LIPID PROFILE FASTING INSULIN OGTT

LH AND FSH: These hormones secreted by the pituitary gland At the beginning of the cycle LH and FSH levels range between 5-20 miu/ml. Most women have equal amounts of LH and FSH during early part of their cycle However there is LH surge before ovulation, LH increases to about 25-40 miu/ml While many women with pcos still have FSH 5-20 miu/ml, their LH level is often 2 or 3 times that of FSH ( elevated LH to FSH ratio) An increased ratio of LH to FSH of >2 is found in 60% to 70% of women with PCOS and is more commonly seen in non-obese women. This change in the LH, FSH ratio is enough to disrupt ovulation While this used to be considered important in diagnosing PCOS it is now considered less useful

TESTING FOR HYPERANDROGENEMIA Done by testosterone levels Total testosterone & Free testosterone single most sensitive test for the detection of androgen excess. Normal upper limit for serum total testosterone in adult women is approximately 40 to 60 ng/dl (1.4 to 2.1nmol/L) Women with pcos have an increased levels of both total and free testosterone A slight increase in testosterone can suppress normal menstruation and ovulation.

Dehydroepiandrosterone sulfate (DHEAS) marker for adrenal hyperandrogenism Used to detect adrenal tumor It is normal for women to have DHEA s level anywhere between 35-430 mcg/dl Most women with PCOS have DHEAS level greater than 200mcg/dl. Adrenal tumor DHEAS levels are often markedly elevated (>700 mcg/dl, 13.6 mmol/l)

PROLACTIN : prolactin levels are ususally normal in women with pcos generally < 25 ng/ml. It is important to check for high prolactin levels in order to rule out pituitary tumors that might be causing PCOS symptoms. Some women with PCOS have (5-30%) have elevated prolactin levels falling within 25-40 ng/ml. ANDROSTENEDIONE: Androstenedione is an hormone produced by the ovaries and adrenal galnds Sometimes high levels can affect estrogen and testosterone levels Normal range- 0.7-3.1 ng/ml

Progesterone: For women with PCOS especially those on fertility treatment, progesterone levels are checked about 7 days after it is thought that ovulation has occurred. If progesterone levels are high ( > 14 ng/ml) this means ovulation has occurred. This test is important because sometimes women with pcos have some signs that ovulation is occurring, however when progesterone tests is done it shows that ovulation did not occur.

Estrogen : Most women with PCOS have their estrogen levels within normal range (25-75 pg/ml). This is due to high levels of insulin and testosterone found in women with pcos are converted to estrogen. TSH: Women with pcos have normal TSH. TSH done to rule out thyroid disesase which cause menstrual irregularities. INSULIN AND GLUCOSE: PCOS caused by insulin resistance. Women should have FBS and GTT at diagnosis Raised fasting insulin >25 micro iu/ml and fasting glucose/insulin ratio <4.5 suggests insulin resistance. Serum insulin levels > 300 after 2 hr 75 glucose load suggests severe IR.

CONCLUSION The Royal College of Obstetricians and Gynaecologists (RCOG) recommends (NOT GUIDELINES!!)the following baseline screening tests for women with suspected polycystic ovarian syndrome (PCOS): Thyroid function tests serum prolactin levels Free androgen index (defined as total testosterone divided by sex hormone binding globulin [SHBG] 100, to give a calculated free testosterone level).

CONCLUSION LH andfsh measurements have sensitivity of only 35% and 41-44%, respectively. Mean serum total testosterone concentration was the most frequent abnormal biochemical marker for PCOS with sensitivity of 70%. Testosterone, androstenedione and LH in combination, increased sensitivity to 86%. Using LH/FSH ratio as a biochemical criterion for diagnosis of PCOS should be abandoned because of its low sensitivity. To be of value the normal range for all hormones should be precisely defined in a group of regularly ovulating women in the early follicular phase of the cycle for the assay used in each laboratory.

CONCLUSION It is important to remember that with all women, hormone levels can very greatly. It is also important to mention that since the normal ranges vary greatly for some hormones (especially since each lab sets its own normal values for these hormones), Also some women with PCOS have hormone levels that appear within the normal range, but still suffer from symptoms and still might have PCOS. Unfortunately, many physicians are not familiar enough with PCOS to understand that even small changes in hormone levels can cause PCOS-related symptoms.

ON GOING RESEARCH Elevated Serum Level of Anti-Mullerian Hormone in Patients with Polycystic Ovary Syndrome has direct Relationship to the Ovarian Follicle Excess and to the Follicular Arrest (Journal of clinical endocrinology JCEM ;2013) A New Contributing Factor to Polycystic Ovary Syndrome: The Genetic Variant of Luteinizing Hormone

THANK YOU

JCEM-AMH In the ovary, AMH is produced by the GC from preantral and small antral follicles. From experimental data, mainly obtained in rodents, the proposed functions of AMH are 1) inhibition of the initial recruitment of primordial follicles, through a paracrine effect 2) inhibition of aromatase activity in GC, thus reducing the production of estradiol (E2). This last effect combined with the fact that AMH could reduce the follicle sensitivity to FSH in the mouse both in vitro and in vivo raises the possibility that an excessive production of AMH could be involved in the follicular arrest of PCOS

Jcem v-lh The high overall frequency of the v-lh β allele in women in general and its low frequency in obese PCOS patients suggest that v-lh has a role in reproductive functions and may somehow contribute to the pathogenesis of PCOS in obese individuals. Although it remains unknown whether the two mutations in v-lh β lead to a net increase or decrease in the overall LH action it is tempting to speculate that it offers advantage or disadvantage to certain individuals depending on their genetic background and environment. Hyperinsulinemia, hyperandrogenism, and dyslipidemia are commonly found in women with PCOS (16, 17). PCOS appears often at a young age, and therefore, we should be able to identify young women at future risk of these hormonal and metabolic changes. As a prognostic or diagnostic approach, the detection of v-lh may allow the discrimination between individuals with high and low risks of PCOS.

The Role of Insulin Resistance/ Hyperinsulinemia in Hyperandrogenism

Diagnostic criteria for insulin resistance syndrome in women Any 3 or more of the following Waist circumference > 88 cm Triglycerides >150mg/dl HDL <50MG/DL FBS> 100MG/DL BP >130/85 mmhg

Hyperinsulinaemia & Hyperandrogenaemia Insulin Receptor Dysfunction Hypothalamus Pancreas LHRH Hyperinsulinaemia Pituitary Liver LH Adrenal Stroma Follicle FSH Reduced SHBG Elevated DHEAS Elevated Androgens Free androgens

Differential diagnosis 1. Virilizing congenital adrenal hyperplasia 2. Cushing s syndrome 3. Virilizing tumors 4. Hyperprolactinemia 5. Insulin-resistance disorders 6. Acromegaly 7. Thyroid dysfunction 8. Drugs